2009 compensation for Bristol-Myers Squibb CEO Cornelius falls 22 percent amid recession The chief executive of drugmaker Bristol-Myers Squibb Co., James Cornelius, received a 2009 compensation package valued by The Associated Press at $17 million, down 22 percent from 2008, due to ...
Executives at Bristol-Myers Squibb Co. told analysts Thursday at a business briefing that the drugmaker has 60 potential drugs in development, seven in late-stage studies, and plenty of money for dealmaking. "Five potential new medicines could be introduced in the next three ...
Key Bristol-Myers drugs in development target cancer types, transplants, heart disease Some key experimental drugs in late-stage testing by biopharmaceutical company Bristol-Myers Squibb Co.: _ipilimumuab, for melanoma, the most dangerous type of skin cancer. Data from a late-stage study could be presented ...
Bristol-Myers expects profit of at least $1.95 a share in 2013, first full year without Plavix Drugmaker Bristol-Myers Squibb Co. said Thursday it expects a profit of at least $1.95 per share in 2013, a crucial period because that's when U.S. generic ...
NEW YORK (Reuters) - Bristol-Myers Squibb Co <BMY.N> set a better-than-expected baseline for profits in 2013 as it provided investors their first glimpse of life after Plavix, the second-largest selling drug in the world. Bristol on Thursday projected 2013 earnings, excluding items, ...
Bristol-Myers Squibb could pay Allergan $413M in licensing deal for neuropathic pain drug Bristol-Myers Squibb and Allergan will jointly attempt to develop a drug to treat chronic pain from tissue damage, the drugmakers said Wednesday. The agreement could eventually be worth $413 ...
Bristol-Myers' Cornelius to retire as CEO, but still head board; COO Andreotti to succeed him Drugmaker Bristol-Myers Squibb Co. said Tuesday its chief executive will retire in May and be succeeded by the current chief operating officer. The move is the fourth ...
In this photo released by Bristol-Myers Squibb Co., newly named CEO Lamberto Andreotti is shown. The drugmaker on Tuesday, March 2, 2010 said Andreotti will serve as CEO effective May 4, when current chairman and CEO James M. Cornelius will retire. (AP ...
<div><p>Biotechnology company Antigenics Inc. on Monday named former Sanofi-Aventis executive Timothy Rothwell to its board of directors.</p><p>Rothwell, 58, was president, chairman and CEO of Sanofi-Aventis U.S. for two years and announced his retirement in February. He has also worked for Pharmacia Corp., ...
<div id="subtitle">Bristol-Myers, Wyeth turn in strong results, wrapping fair quarter for pharmaceutical industry</div><div><p>Bristol-Myers Squibb Co. and Wyeth on Thursday turned in two of the drug industry's best second-quarter performances, with both reporting strong profit growth and sailing past Wall Street expectations as ...
